FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2894799643> ?p ?o ?g. }

• W2894799643 endingPage "163" @default.
• W2894799643 startingPage "154" @default.
• W2894799643 abstract "5F-CUMYL-PEGACLONE is a recently emerged γ-carbolinone derived synthetic cannabinoid. The present study aimed to identify phase I metabolites to reliably prove consumption of the substance by urine analysis and to differentiate from the uptake of the non-fluorinated analog CUMYL-PEGACLONE. For metabolite characterization, phase I metabolites were analyzed by liquid chromatography–high resolution mass spectrometry after incubation with pooled human liver microsomes. Reliability of the biomarkers was evaluated by analysis of human urine samples (n = 20) by liquid chromatography–triple quadrupole tandem mass spectrometry. Sample preparation included β-glucuronidase treatment followed by liquid-liquid extraction. In total, 15 metabolites were detected in vivo and characterized. Metabolic reactions were primarily observed at the γ-carbolinone core and the 5-fluoropentyl chain, and included N-dealkylation, hydroxylation, hydrolytic defluorination, formation of a dihydrodiol, oxidation to the pentanoic acid metabolite and formation of the propionic acid metabolite. Six of these metabolites were identical with phase I metabolites of CUMYL-PEGACLONE, which must be considered for interpretation of analytical findings in urine samples. 5F-CUMYL-PEGACLONE was subject to extensive metabolism in humans. The propionic acid metabolite was the most abundant metabolite in all urine samples and should be targeted when maximum sensitivity is needed (e.g., drug abstinence control). However, this metabolite also occurs in the biotransformation of the non-fluorinated analog and is, therefore, not a compound-specific marker. For differentiation, a metabolite hydroxylated at the γ-carbolinone core showed to be the most reliable marker and should be used as an additional target analyte." @default.
• W2894799643 created "2018-10-12" @default.
• W2894799643 creator A5004340821 @default.
• W2894799643 creator A5030841627 @default.
• W2894799643 creator A5040440723 @default.
• W2894799643 creator A5044491161 @default.
• W2894799643 creator A5064596365 @default.
• W2894799643 date "2018-10-05" @default.
• W2894799643 modified "2023-10-18" @default.
• W2894799643 title "Human phase I metabolism of the novel synthetic cannabinoid 5F-CUMYL-PEGACLONE" @default.
• W2894799643 cites W1855306715 @default.
• W2894799643 cites W1971590308 @default.
• W2894799643 cites W2020125001 @default.
• W2894799643 cites W2021178430 @default.
• W2894799643 cites W2024053795 @default.
• W2894799643 cites W2048921576 @default.
• W2894799643 cites W2186697446 @default.
• W2894799643 cites W2211259886 @default.
• W2894799643 cites W2492836649 @default.
• W2894799643 cites W2530030091 @default.
• W2894799643 cites W2593385402 @default.
• W2894799643 cites W2595397629 @default.
• W2894799643 cites W2604497858 @default.
• W2894799643 cites W2620523760 @default.
• W2894799643 cites W2724651776 @default.
• W2894799643 cites W2726332868 @default.
• W2894799643 cites W2742841490 @default.
• W2894799643 cites W2743959781 @default.
• W2894799643 cites W2751534537 @default.
• W2894799643 cites W2781924776 @default.
• W2894799643 cites W2801605997 @default.
• W2894799643 doi "https://doi.org/10.1007/s11419-018-0447-4" @default.
• W2894799643 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6315001" @default.
• W2894799643 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30636984" @default.
• W2894799643 hasPublicationYear "2018" @default.
• W2894799643 type Work @default.
• W2894799643 sameAs 2894799643 @default.
• W2894799643 citedByCount "17" @default.
• W2894799643 countsByYear W28947996432019 @default.
• W2894799643 countsByYear W28947996432020 @default.
• W2894799643 countsByYear W28947996432021 @default.
• W2894799643 countsByYear W28947996432022 @default.
• W2894799643 countsByYear W28947996432023 @default.
• W2894799643 crossrefType "journal-article" @default.
• W2894799643 hasAuthorship W2894799643A5004340821 @default.
• W2894799643 hasAuthorship W2894799643A5030841627 @default.
• W2894799643 hasAuthorship W2894799643A5040440723 @default.
• W2894799643 hasAuthorship W2894799643A5044491161 @default.
• W2894799643 hasAuthorship W2894799643A5064596365 @default.
• W2894799643 hasBestOaLocation W28947996431 @default.
• W2894799643 hasConcept C150903083 @default.
• W2894799643 hasConcept C162356407 @default.
• W2894799643 hasConcept C170493617 @default.
• W2894799643 hasConcept C181199279 @default.
• W2894799643 hasConcept C185592680 @default.
• W2894799643 hasConcept C192989942 @default.
• W2894799643 hasConcept C207001950 @default.
• W2894799643 hasConcept C21565614 @default.
• W2894799643 hasConcept C2777477808 @default.
• W2894799643 hasConcept C2777846614 @default.
• W2894799643 hasConcept C2778961205 @default.
• W2894799643 hasConcept C2780026642 @default.
• W2894799643 hasConcept C2780035454 @default.
• W2894799643 hasConcept C2780871563 @default.
• W2894799643 hasConcept C2781109383 @default.
• W2894799643 hasConcept C27881333 @default.
• W2894799643 hasConcept C43617362 @default.
• W2894799643 hasConcept C55493867 @default.
• W2894799643 hasConcept C62231903 @default.
• W2894799643 hasConcept C81426234 @default.
• W2894799643 hasConcept C86803240 @default.
• W2894799643 hasConcept C89311334 @default.
• W2894799643 hasConcept C98274493 @default.
• W2894799643 hasConceptScore W2894799643C150903083 @default.
• W2894799643 hasConceptScore W2894799643C162356407 @default.
• W2894799643 hasConceptScore W2894799643C170493617 @default.
• W2894799643 hasConceptScore W2894799643C181199279 @default.
• W2894799643 hasConceptScore W2894799643C185592680 @default.
• W2894799643 hasConceptScore W2894799643C192989942 @default.
• W2894799643 hasConceptScore W2894799643C207001950 @default.
• W2894799643 hasConceptScore W2894799643C21565614 @default.
• W2894799643 hasConceptScore W2894799643C2777477808 @default.
• W2894799643 hasConceptScore W2894799643C2777846614 @default.
• W2894799643 hasConceptScore W2894799643C2778961205 @default.
• W2894799643 hasConceptScore W2894799643C2780026642 @default.
• W2894799643 hasConceptScore W2894799643C2780035454 @default.
• W2894799643 hasConceptScore W2894799643C2780871563 @default.
• W2894799643 hasConceptScore W2894799643C2781109383 @default.
• W2894799643 hasConceptScore W2894799643C27881333 @default.
• W2894799643 hasConceptScore W2894799643C43617362 @default.
• W2894799643 hasConceptScore W2894799643C55493867 @default.
• W2894799643 hasConceptScore W2894799643C62231903 @default.
• W2894799643 hasConceptScore W2894799643C81426234 @default.
• W2894799643 hasConceptScore W2894799643C86803240 @default.
• W2894799643 hasConceptScore W2894799643C89311334 @default.
• W2894799643 hasConceptScore W2894799643C98274493 @default.
• W2894799643 hasIssue "1" @default.
• W2894799643 hasLocation W28947996431 @default.

• next